GLPwatch
In adults with BMI ≥27 kg/m<sup>2</sup> and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
Ann Intern Med · 2023
Last updated 2026-05-28In a study of 938 adults with a BMI of at least 27 kg/m² and type 2 diabetes, adding the medication tirzepatide to lifestyle changes led to greater weight loss over 72 weeks compared to a placebo. Participants taking tirzepatide lost an average of 14.7% of their body weight, while those on placebo lost 3.2%.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2023 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.17 |
| NIH percentile | 11 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Lancet. 2023;402:613-626. 37385275.
Verbatim abstract via PubMed 37931265 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.